2007-04-11T00:00:00
The World Health Organisation has welcomed the decision of Abbott Laboratories to significantly reduce the price of lopinavir/ritonavir, a second-line antiretroviral therapy to help in the fight against HIV/AIDS.
With a HSJ subscription you’ll unlock:
Already a subscriber? Sign into your account here
Part of HSJ Information Ltd. The White Chapel Building, 1st Floor, 10 Whitechapel High Street, London, E1 8QS. Registered in England and Wales. Company registration 2530185
Site powered by Webvision Cloud